Our latest deals : Domain Therapeutics ($42M series A), Ludocare (€4.2M Seed), Spine Innovations (M&A sell-side, un-disclosed amount), Neurofenix ($7M series A), Incepto (€27M series B)
|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.
Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
Founded in 2018, Incepto is a unique platform on the market that offers doctors and hospitals access to a portfolio of solutions based on artificial intelligence, designed to improve the quality of diagnoses, and save time for medical teams, without having to change equipment. In order to support its growth at a European scale, Incepto is raising €27 million today.
Bordeaux, France, September 5, 2022 – FineHeart S.A, a preclinical medical device company that has developed the ICOMS FLOWMAKER®, a fully Implantable Cardiac Output Management System designed to address the unmet need of patients suffering from severe heart failure, today announced its ISO 13485 : 2016 certification. This certifies the compliance of FineHeart’s quality management system with medical device industry regulations and has been issued following an audit by BSI, the independent, internationally recognized, accreditation organization.
Digital neuro-rehabilitation platform Neurofenix, which is helping to revolutionise remote rehabilitation for stroke patients, has secured $7million to help fuel its expansion and fund clinical trials in the United States.
|SUCCES DE LA PREMIERE OPERATION DE RECONSTRUCTION MAMMAIRE AVEC MATTISSE 🚀|
Le 12 juillet 2022, une première patiente atteinte d’un cancer du sein a pu bénéficier d’une reconstruction mammaire grâce à notre implant #MATTISSE.
Paris, France, September 26, 2022 – 06:00pm CEST – ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical-stage biotechnology company developing innovative drugs for the treatment of cardiovascular emergencies, particularly stroke, today announced the enrollment of the first patient in the USA in its Phase 2/3 registration study ACTISAVE, which is evaluating glenzocimab in patients with acute ischemic stroke.
Launch of Vik Atopic Dermatitis in Arabic
After taking Vik Atopic Dermatitis to 9 countries and in four different languages, our main goal remains guiding patients through their search for a healthier life.
Latest Insights
[INNOVER CONTRE LE CANCER 5/5] Si certains acteurs se concentrent sur le diagnostic ou le traitement du cancer, d’autres développent des produits et services pour soulager le quotidien des patients. Maddyness a sélectionné une liste non exhaustive de solutions pour les accompagner dans la maladie.
Paris, France, July 10, 2017 – The European Investment Bank (EIB) and Cellnovo Group (“Cellnovo” or the “Company” CLNV:EN Paris), a
TransCure bioServices is proud to announce that our facility is now fully accredited by the AAALAC, a compelling achievement rewarding hard-work and dedication to the humane and responsible care and use of animals.
Selon, l’Organisation mondiale de la Santé, plus de 700 000 personnes sont mortes par suicide en 2019, classant l’acte suicidaire en 4ème cause de mort après les accidents de la route, la tuberculose et la violence interpersonnelle chez les 15 à 29 ans1 . Le suicide est souvent perçu comme un acte spontané. Cependant, la majorité des personnes qui se suicident expriment leurs pensées sur la mort ou le suicide bien avant le passage à l’acte. L’analyse de telles propos, retrouvés sur les plateformes d’échanges, permet une identification précoce de signaux d’alertes.
Paris, July 17, 2018, 18h00 CET – EOS imaging (Euronext, FR0011191766 – EOSI), the pioneer of orthopedicmedical imaging 2D / 3D,